Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221063 | 1.00 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL221064 | 1.00 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL771264 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL15472723 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL17181765 | 0.93 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL184777 | 0.93 | CYP2D6 (0.60) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL2298971 | 0.90 | CYP2D6 (0.49) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL28719877 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL5447212 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL19001727 | 0.88 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039201-A | Synthesis method of (S) -1-tert-butoxycarbonyl-3-aminopyrrolidine | 苏州汉德创宏生化科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| CN-116768861-B | SOS1 protein degradation targeting chimeric and composition, preparation and application thereof | 北京福元医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| CN-115677601-B | Compound with anti-tumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250042857-A1 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | HAIHE BIOPHARMA CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| US-6335445-B1 | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-01 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| US-6252088-B1 | COUPLING A NITRILE CONTAININ NAPHTHALENE COMPOUND WITH A COMPOUND CONTAINING PROPIONIC ACID GROUP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-5977097-A | 1-methylcarbapenem derivatives | SANKYO COMPANY LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0936215-A1 | PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0900797-A1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0491943-A4 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RORER INT HOLDINGS (US) | 1996-02-14 | — | — | EP | disclosed |
| EP-0491943-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1992000295-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | CYP2D6 1479/4885GPR119 3369/4885MMP13 4376/4885 |
| US-20250042857-A1 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | SOS1, MEN1, BRCA1 | CYP2D6 1504/4885GPR119 2819/4885MMP13 4375/4885 |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | CYP2D6 1445/4885GPR119 245/4885MMP13 3483/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | CYP2D6 1038/4885GPR119 418/4885MMP13 4835/4885 |
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | CYP2D6 853/4885GPR119 1523/4885MMP13 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.